Recursion Pharmaceuticals, Inc. RXRX Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization?
- Recursion Pharmaceuticals, Inc. (RXRX) reported finite-lived intangible assets, accumulated amortization of $87.63M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization increased by 127.2% year-over-year, from $38.57M to $87.63M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization has grown at a 259.0% compound annual growth rate (CAGR), from $127K to $75.78M.